A Clinical Study to Evaluate the Relative Bioavailability of FDC Tablets Containing Enlicitide and Rosuvastatin, Compared to Enlicitide and Rosuvastatin Administered Concomitantly as Single Entities, in Healthy Adult Participants
Latest Information Update: 22 Jun 2026
At a glance
- Drugs Enlicitide/rosuvastatin calcium (Primary) ; Enlicitide; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Acronyms MK-0616-039
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 09 Jun 2026 Planned End Date changed from 14 Oct 2026 to 21 Oct 2026.
- 09 Jun 2026 Planned primary completion date changed from 7 Oct 2026 to 14 Oct 2026.
- 28 May 2026 Status changed from active, no longer recruiting to recruiting.